Medigene AG: Medigene's Drug Veregen® Launched in Canada

           Medigene AG: Medigene's Drug Veregen® Launched in Canada  Medigene AG / Medigene's Drug Veregen® Launched in Canada . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.  Press release  Martinsried/Munich,  July  17,  2014.  Medigene  AG  (MDG1,  Frankfurt,  Prime  Standard) announces the launch of its drug Veregen^® (Sinecatechins  Ointment,  10%) for  the treatment  of  genital warts  in  Canada through  the  marketing  partner Paladin Labs Inc. (who acquired  Triton Pharma). Within the scope  of  the license agreement, Medigene receives  sales milestone payments as well  as  royalties on Veregen^® sales.  Up to  now,  Veregen^® is  available  in the  USA,  in 15  European  countries  (Germany, Austria,  Switzerland,  Spain,  Serbia,  the  Netherlands,  Belgium,  Norway, Sweden,  Denmark,  Finland,  Czech Republic,  Slovakia,  Hungary,  and  Poland), and in Taiwan. The drug has  obtained market approval in a number  of  additional countries.  Several  marketing  partnership  agreements  have  been  concluded in Europe, Asia, and America.  About Veregen^®:  Veregen^®,  a  topical treatment  for  external  genital  or  perianal warts, contains  a concentrate  of catechins with  a complex  defined  composition extracted from green tea leaves. Sinecatechins 10% & 15%  Ointment  (Veregen^®)  has  been  included  in  the  2012  European  Guideline  for  the  Management  of  Anogenital  Warts.  In  addition,  in  its  current  Sexually  Transmitted Diseases Treatment Guidelines, the US Centers for Disease  Control  and Prevention includes Sinecatechins 15%  Ointment (Veregen^®) as a  possible  option for treating genital warts.  About Paladin Labs Inc.: Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty  pharmaceutical company  focused on  acquiring or  in-licensing  innovative pharmaceutical products for  Canadian and select emerging  markets.  Paladin has a  focused marketing  and sales  organization that  has helped  it  evolve into  one  of  Canada's  leading  specialty  pharmaceutical  companies.  Paladin is an operating company of Endo International plc, a global  specialty  healthcare  company  focused  on  improving  patients'  lives  while  creating  shareholder value. Learn more at www.endo.com.  Medigene  AG  is   a  publicly  listed   (Frankfurt:  MDG1,  prime   standard)  biotechnology company  headquartered  in  Martinsried  near  Munich,  Germany.  Medigene  concentrates   on   the   development   of   personalized   T   cell  immunotherapies with  focus on  haematological malignancies.  Medigene is  the  first German biotech company to have  revenues from a marketed product,  which  is distributed by commercial partners. Medigene has various drug candidates in clinical  development  and  it  is  developing  highly  innovative   treatment  platforms. For more information, please visit www.medigene.de.  This  press  release  contains  forward-looking  statements  representing  the  opinion of  Medigene  as of  the  date of  this  release. The  actual  results  achieved  by  Medigene  may  differ  significantly  from  the  forward-looking  statements made  herein.  Medigene  is  not  bound  to  update  any  of  these  forward-looking statements. Medigene^® and Veregen^® are registered trademarks of Medigene AG. Polyphenon E^® is a trademark of Mitsui Norin Co., Ltd.  These  trademarks may be owned or licensed in select locations only.  Contact Julia Hofmann, Anja Clausnitzer Tel.: +49 - 89 - 20 00 33 - 33 01 Email: investor@medigene.com  To unsubscribe  from  the  press  release distribution  list,  please  go  to:  www.medigene.de/unsubscribe  Press release as PDF  ------------------------------------------------------------------------------  This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Medigene AG via Globenewswire HUG#1827750  --- End of Message ---  Medigene AG Lochhamer Strasse 11 Martinsried / München Germany  WKN: A1X3W0;ISIN: DE000A1X3W00; Listed: Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Bayerische Börse München, Freiverkehr in Niedersächsische Börse zu Hannover, Prime Standard in Frankfurter Wertpapierbörse, Regulierter Markt in Frankfurter Wertpapierbörse;  
Press spacebar to pause and continue. Press esc to stop.